Pharmacophore modeling and in silico toxicity assessment of potential anticancer agents from African medicinal plants
暂无分享,去创建一个
Wolfgang Sippl | Fidele Ntie-Kang | Philip Neville Judson | Berin Karaman | Conrad Veranso Simoben | Valery Fuh Ngwa | P. Judson | W. Sippl | Berin Karaman | C. V. Simoben | F. Ntie‐Kang | L. M. Mbaze | Luc Meva’a Mbaze
[1] R. M. Jayadeepa,et al. Anti cancer activity on Graviola, an exciting medicinal plant extract vs various cancer cell lines and a detailed computational study on its potent anti-cancerous leads. , 2013, Current topics in medicinal chemistry.
[2] Hsuan-Liang Liu,et al. Structure-based pharmacophore modeling and virtual screening to identify novel inhibitors for anthrax lethal factor , 2014, Medicinal Chemistry Research.
[3] J. Kuriyan,et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. , 2002, Cancer research.
[4] Y. Zhan,et al. Furanocoumarins-imperatorin inhibits myocardial hypertrophy both in vitro and in vivo. , 2010, Fitoterapia.
[5] A. Kinghorn,et al. The relevance of higher plants in lead compound discovery programs. , 2011, Journal of natural products.
[6] D. Newman,et al. Nature: a vital source of leads for anticancer drug development , 2009, Phytochemistry Reviews.
[7] I. Muegge. Selection criteria for drug‐like compounds , 2003, Medicinal research reviews.
[8] Ian Collins,et al. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. , 2007, Journal of medicinal chemistry.
[9] C. Marchant,et al. Computational toxicology: a tool for all industries , 2012 .
[10] K. Lee,et al. Anticancer drug design based on plant-derived natural products. , 1999, Journal of biomedical science.
[11] C. Terreaux,et al. Search for New Lead Compounds from Higher Plants , 2000, CHIMIA.
[12] R. Ganju,et al. Medicinal plants and cancer chemoprevention. , 2008, Current drug metabolism.
[13] H. El‐Seedi,et al. The traditional medical uses and cytotoxic activities of sixty-one Egyptian plants: discovery of an active cardiac glycoside from Urginea maritima. , 2013, Journal of ethnopharmacology.
[14] W. Denny,et al. The genetic toxicology of acridines. , 1991, Mutation research.
[15] H. Hussain,et al. Antimicrobial Coumarins from the Stem Bark of Afraegle paniculata , 2010, Natural product communications.
[16] Andrew Marston,et al. The Potential of African Plants as a Source of Drugs , 2000 .
[17] P N Judson,et al. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. , 1999, SAR and QSAR in environmental research.
[18] Michael M. Mysinger,et al. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.
[19] J E Ridings,et al. Computer prediction of possible toxic action from chemical structure: an update on the DEREK system. , 1996, Toxicology.
[20] Steven Fletcher,et al. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. , 2009, Chemistry & biology.
[21] Connors. Anticancer Drug Development: The Way Forward. , 1996, The oncologist.
[22] Kazuhiro Uemoto,et al. Pharmacophore-based design of sphingosine 1-phosphate-3 receptor antagonists that include a 3,4-dialkoxybenzophenone scaffold. , 2007, Journal of medicinal chemistry.
[23] K. Bhoola,et al. Natural products for cancer prevention: a global perspective. , 2003, Pharmacology & therapeutics.
[24] Valerie J. Gillet,et al. Automating Knowledge Discovery for Toxicity Prediction Using Jumping Emerging Pattern Mining , 2012, J. Chem. Inf. Model..
[25] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[26] Hsuan-Liang Liu,et al. The discovery of potential acetylcholinesterase inhibitors: A combination of pharmacophore modeling, virtual screening, and molecular docking studies , 2011, Journal of Biomedical Science.
[27] Pascal Amoa Onguéné,et al. CamMedNP: Building the Cameroonian 3D structural natural products database for virtual screening , 2013, BMC Complementary and Alternative Medicine.
[28] F. Dall'acqua,et al. Investigation of the dark interaction between furocoumarins and DNA. , 1978, Chemico-biological interactions.
[29] G. Klebe. Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.
[30] Sven Hellberg,et al. Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. , 2012, Journal of medicinal chemistry.
[31] Wolfgang Sippl,et al. AfroDb: A Select Highly Potent and Diverse Natural Product Library from African Medicinal Plants , 2013, PloS one.
[32] H. D. Showalter,et al. Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. , 2000, Biochemical pharmacology.
[33] D. Newman,et al. Impact of natural products on developing new anti-cancer agents. , 2009, Chemical reviews.
[34] Tetsuya Kohno,et al. Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors. , 2014, ACS medicinal chemistry letters.
[35] Dharmaranjan Sriram,et al. Enhanced ranking of PknB Inhibitors using data fusion methods , 2013, Journal of Cheminformatics.
[36] Ying Sun,et al. Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. , 2008, Journal of medicinal chemistry.
[37] Y. Chin,et al. Drug Discovery from Plants , 2008 .
[38] Ping-Chiang Lyu,et al. Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. , 2009, Journal of medicinal chemistry.
[39] M. Gordaliza. Natural products as leads to anticancer drugs , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[40] D. Sanderson,et al. Computer Prediction of Possible Toxic Action from Chemical Structure; The DEREK System , 1991, Human & experimental toxicology.
[41] D. Newman,et al. Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.
[42] S. Capaccioli,et al. Natural compounds for cancer treatment and prevention. , 2009, Pharmacological research.
[43] Michael M. Hann,et al. RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..
[44] A. Kinghorn,et al. The continuing search for antitumor agents from higher plants. , 2010, Phytochemistry letters.
[45] Jürg Zimmermann,et al. Potent and Selective Inhibitors of the AbL-Kinase: Phenylaminopyrimidine (PAP) Derivatives. , 1997 .
[46] D. Averbeck,et al. Frameshift mutagenicity in Salmonella typhimurium of furocoumarins in the dark. , 1984, Mutation research.
[47] D J Newman,et al. Plants as a source of anti-cancer and anti-HIV agents , 2003 .
[48] Peter M Fischer,et al. Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. , 2010, Chemistry & biology.
[49] Roberto Battistutta,et al. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. , 2011, Biochemistry.
[50] Zigang Dong,et al. Prediction of Molecular Targets of Cancer Preventing Flavonoid Compounds Using Computational Methods , 2012, PloS one.
[51] K. Lee,et al. Plant-derived anticancer agents and their analogs currently in clinical use or in clinical trials , 1997 .
[52] Christopher T. Walsh,et al. Lessons from natural molecules , 2004, Nature.
[53] Gajendra P. S. Raghava,et al. NPACT: Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target database , 2012, Nucleic Acids Res..
[54] D. Newman,et al. Plant Natural Products in Anticancer Drug Discovery , 2010 .
[55] M. Grever,et al. Potential of plant-derived natural products in the treatment of leukemia and lymphoma. , 2010, Current drug targets.
[56] J. Gibbs. Mechanism-based target identification and drug discovery in cancer research. , 2000, Science.
[57] John Kuriyan,et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.
[58] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[59] W. Sippl,et al. Binding of pyrazole-based inhibitors to Mycobacterium tuberculosis pantothenate synthetase: docking and MM-GB(PB)SA analysis. , 2014, Molecular bioSystems.
[60] M. Wani,et al. Plant antimutagenic agents, 1. General bioassay and isolation procedures. , 1988, Journal of natural products.
[61] Ian Collins,et al. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. , 2008, Journal of medicinal chemistry.
[62] S. Efange,et al. Natural products: a continuing source of inspiration for the medicinal chemist , 2002 .
[63] J N Weinstein,et al. Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies. , 2001, Journal of medicinal chemistry.
[64] Philip N. Judson,et al. How “drug-like” are naturally occurring anti-cancer compounds? , 2014, Journal of Molecular Modeling.
[65] Zhaohui J. Cai,et al. Pretreatment data is highly predictive of liver chemistry signals in clinical trials , 2012, Drug design, development and therapy.
[66] D. Newman,et al. Plants as a source of anti-cancer agents. , 2005, Journal of ethnopharmacology.
[67] David J Newman,et al. Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.
[68] T. Efferth,et al. Gems from traditional north-African medicine: medicinal and aromatic plants from Sudan , 2012, Natural Products and Bioprospecting.
[69] Lilly M Saleena,et al. Discovery of potent inhibitor for matrix metalloproteinase-9 by pharmacophore based modeling and dynamics simulation studies. , 2014, Journal of molecular graphics & modelling.
[70] Tom Fawcett,et al. An introduction to ROC analysis , 2006, Pattern Recognit. Lett..
[71] Tsai-Wei Shen,et al. A pharmacophore‐based evolutionary approach for screening selective estrogen receptor modulators , 2005, Proteins.
[72] A. Gurib-Fakim,et al. Medicinal plants: traditions of yesterday and drugs of tomorrow. , 2006, Molecular aspects of medicine.
[73] N. Greene. Computer Software for Risk Assessment , 1997, J. Chem. Inf. Comput. Sci..
[74] Wolfgang Sippl,et al. In silico drug metabolism and pharmacokinetic profiles of natural products from medicinal plants in the Congo basin , 2013, In Silico Pharmacology.
[75] G. Aherne,et al. Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)† , 2010, Journal of medicinal chemistry.
[76] A. Negi,et al. Plant-Based Anticancer Molecules: A Chemical and Biological Profile of Some Important Leads , 2012 .
[77] J W Yates,et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.
[78] Kazuo Kitaura,et al. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds. , 2012, Journal of medicinal chemistry.
[79] Fang Wang,et al. Optimized S-Trityl-l-cysteine-Based Inhibitors of Kinesin Spindle Protein with Potent in Vivo Antitumor Activity in Lung Cancer Xenograft Models , 2013, Journal of medicinal chemistry.
[80] Wolfgang Sippl,et al. Molecular Modeling of Potential Anticancer Agents from African Medicinal Plants , 2014, J. Chem. Inf. Model..
[81] Marcy J. Balunas,et al. Drug discovery from medicinal plants. , 2005, Life sciences.
[82] W. Muster,et al. Suppression of mutagenic activity of a series of 5HT2c receptor agonists by the incorporation of a gem-dimethyl group: SAR using the Ames test and a DNA unwinding assay. , 1998, Mutagenesis.
[83] H. El‐Seedi,et al. A Swedish collection of medicinal plants from Cameroon. , 2005, Journal of ethnopharmacology.
[84] Thierry Langer,et al. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..
[85] Heng Tao Shen,et al. Principal Component Analysis , 2009, Encyclopedia of Biometrics.
[86] V. Vyas,et al. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors. , 2013, Journal of molecular graphics & modelling.
[87] Marc Schumacher,et al. Traditional West African pharmacopeia, plants and derived compounds for cancer therapy. , 2012, Biochemical pharmacology.
[88] Ki Young Lee,et al. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. , 2006, Journal of medicinal chemistry.
[89] G. Kéri,et al. Plant-derived protein tyrosine kinase inhibitors as anticancer agents. , 2004, Current medicinal chemistry. Anti-cancer agents.
[90] M. Heinrich,et al. Ethnobotany and ethnopharmacy--their role for anti-cancer drug development. , 2006, Current drug targets.
[91] L. Pardo,et al. Synthesis and pharmacophore modeling of naphthoquinone derivatives with cytotoxic activity in human promyelocytic leukemia HL-60 cell line. , 2007, Journal of medicinal chemistry.
[92] Adam Siddiqui-Jain,et al. Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells. , 2012, Bioorganic & medicinal chemistry letters.
[93] Wolfgang Sippl,et al. The potential of anti-malarial compounds derived from African medicinal plants, part III: an in silico evaluation of drug metabolism and pharmacokinetics profiling , 2014, Organic and medicinal chemistry letters.
[94] Adam Siddiqui-Jain,et al. 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. , 2011, Bioorganic & medicinal chemistry letters.
[95] S. Kuduk,et al. A common pharmacophore for cytotoxic natural products that stabilize microtubules. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[96] P. Judson,et al. Assessing the pharmacokinetic profile of the CamMedNP natural products database: an in silico approach , 2013, Organic and medicinal chemistry letters.
[97] Arvind Saklani,et al. Plant-derived compounds in clinical trials. , 2008, Drug discovery today.
[98] Wolfgang Sippl,et al. ConMedNP: a natural product library from Central African medicinal plants for drug discovery , 2014 .
[99] Fidele Ntie-Kang,et al. Virtualizing the p-ANAPL Library: A Step towards Drug Discovery from African Medicinal Plants , 2014, PloS one.
[100] S. A. Fadeyi,et al. In vitro anticancer screening of 24 locally used Nigerian medicinal plants , 2013, BMC Complementary and Alternative Medicine.
[101] Jürg Zimmermann,et al. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives , 1997 .
[102] D J Newman,et al. The influence of natural products upon drug discovery. , 2000, Natural product reports.
[103] P. Willett,et al. PHARMACOPHORE PERCEPTION , DEVELOPMENT , AND USE IN DRUG DESIGN , 2011 .
[104] H. Kubinyi. Structure-based design of enzyme inhibitors and receptor ligands. , 1998, Current opinion in drug discovery & development.
[105] Carol A Marchant,et al. In Silico Tools for Sharing Data and Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic , 2008, Toxicology mechanisms and methods.